We are live on ! Find out more
MNTA

Momenta Pharmaceuticals, Inc.
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

166 hedge funds and large institutions have $1.05B invested in Momenta Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 68 increasing their positions, 44 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 44

45% more call options, than puts

Call options by funds: $3.76M | Put options by funds: $2.59M

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

5% more funds holding

Funds holding: 158166 (+8)

23% less capital invested

Capital invested by funds: $1.36B → $1.05B (-$308M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
166
Holders Change
+8
Holders Change %
+5.06%
% of All Funds
3.76%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
26
Increased
68
Reduced
44
Closed
18
Calls
$3.76M
Puts
$2.59M
Net Calls
+$1.17M
Net Calls Change
-$1.84M

MNTA Hedge Fund Activity: Q4 2017 in Review

166 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q4 2017, worth a combined $1.05B — down 23% from $1.36B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new MNTA positions and 18 closed out — a net gain of 8 holders — while 68 added to existing stakes and 44 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $20.7M. The largest seller was OrbiMed, cutting an estimated $13.3M.

  • 166 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q4 2017, up from 158 in Q3 2017.
  • Funds reported $1.05B of Momenta Pharmaceuticals, Inc. stock for Q4 2017, down 23% quarter-over-quarter.
  • 26 funds opened new Momenta Pharmaceuticals, Inc. positions in Q4 2017 and 18 closed out, a net change of +8 holders.
  • The largest Momenta Pharmaceuticals, Inc. buyer in Q4 2017 was Wellington Management Group, an estimated $20.7M added.
  • The largest Momenta Pharmaceuticals, Inc. seller in Q4 2017 was OrbiMed, an estimated $13.3M sold.

Based on aggregated 13F filings for Q4 2017.